Ocugen Announces Positive Data From Retinitis Pigmentosa Study

(RTTNews) - Ocugen, Inc. (OCGN), Monday announced safety and efficacy update for the Phase 1/2 OCU400 clinical trial for the treatment of early to advanced retinitis pigmentosa in pediatric and adult populations.

OCU400, a modifier gene therapy product - based on a nuclear hormone receptor gene called NR2E3, demonstrated improvement in low-luminance visual acuity as well as effectiveness across multiple mutations.

The company added that the ongoing phase 3 OCU400 liMeliGhT clinical trial is on target for BLA submission in the first half of 2026.

In the pre-market hours, Ocugen's stock is trading at $0.799, up 1.58 percent on the Nasdaq.